Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For primary hyperlipidemia. Sold as Zypitamag. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pitavastatin Magnesium (sold as Zypitamag), first approved Jul 14, 2017, with 0 new uses approved and 0 published complete response letters.
First approved: Jul 14, 2017
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.1M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Zypitamag
Part D
$3.1M
-22%
2,010
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
PITAVASTATIN 1 MG TABLET: $0.837 per unitGeneric · -48% in a year
PITAVASTATIN 2 MG TABLET: $0.969 per unitGeneric · -30% in a year
PITAVASTATIN 4 MG TABLET: $0.989 per unitGeneric · -34% in a year
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
LivaloDrugs with a new additional pediatric dosage indicated for the treatment of familial hypercholesterolemia. · Kowa Company, Ltd. · Jun 26, 2015 · Review report
LivaloDrugs with a new dosage indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. · Kowa Company, Ltd. · Feb 28, 2013
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
